Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T15:12:50.126Z.
Calculation as of: 2026-10-06T15:12:50.126Z.
Quote observation: 2026-10-06T15:10:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6608cd76dc650ef8b2fc8232603ca313d9f3e0951a45c9e65e7ec74b346396eb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Karyopharm Therapeutics Inc.
Market Cap
$14.67M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.37M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.04M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.00M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.78M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.58M
Operating Cash Flow Yield
N/A
TTM Avg
1.78%
3Y Avg
1.78%
5Y Avg
1.78%
Market Cap
$13.72M
Operating Cash Flow Yield
3.82%
TTM Avg
3.56%
3Y Avg
3.56%
5Y Avg
3.56%
Market Cap
$15.75M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | $14.67M | N/A | N/A | N/A | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.37M | N/A | N/A | N/A | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.04M | N/A | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.00M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $13.78M | N/A | N/A | N/A | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.58M | N/A | 1.78% | 1.78% | 1.78% |
| Vyome Holdings, Inc. (HIND)vs › | $13.72M | 3.82% | 3.56% | 3.56% | 3.56% |
| IN8bio, Inc. (INAB)vs › | $13.62M | N/A | N/A | N/A | N/A |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.75M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $13.29M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
